A novel synthetic bipartite carrier protein for developing glycotope-based vaccines

Vaccine

Volumn 30, Issue 52, 2012, Pages 7573-7581

  Chiang, Hsiao Ling ^a,b,g   Lin, Chi Yu ^a,b,g   Jan, Fan Dan ^c   Lin, Yaoh Shiang ^d   Hsu, Chia Tse ^b   Whang Peng, Jacqueline ^e   Liu, Leroy F ^f   Nieh, Shin ^a,d   Lin, Chun Cheng ^c   Hwang, Jaulang ^a,b,g  

^a NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^b INSTITUTE OF MOLECULAR BIOLOGY   (Taiwan)

^c NATIONAL TSING HUA UNIVERSITY   (Taiwan)

^d TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^e TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^f RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^g TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Carrier protein; Glycotope; Tn antigen; Tumor immunotherapy; Vaccine

Indexed keywords

ANTIGEN; ANTINEOPLASTIC AGENT; BIPARTITE CARRIER PROTEIN; CANCER VACCINE; CARRIER PROTEIN; EPITOPE; FC RECEPTOR; GLYCOTOPE; IMMUNOGLOBULIN G1 ANTIBODY; MFC(CYSTEINE TN)HISTAG VACCINE; MONOSACCHARIDE; RFC(CYSTEINE TN)HISTAG VACCINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ANTIGEN PRESENTING CELL; ARTICLE; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; DRUG CONJUGATION; DRUG DESIGN; DRUG EFFICACY; FEMALE; MOLECULAR DOCKING; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; TRANSGENIC ANIMAL; TUMOR XENOGRAFT;

ADENOCARCINOMA; ANIMALS; ANTIGEN-PRESENTING CELLS; ANTIGENS, NEOPLASM; B-LYMPHOCYTES; CANCER VACCINES; CARBOHYDRATE METABOLISM; CARBOHYDRATES; CARRIER PROTEINS; DISEASE MODELS, ANIMAL; FEMALE; MALE; MICE; MICE, INBRED BALB C; PROSTATIC NEOPLASMS; PROTEIN BINDING; RABBITS;

EID: 84870516343     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.10.041     Document Type: Article

References (43)

1. Ragupathi G. Carbohydrate antigens as targets for active specific immunotherapy. Cancer Immunol Immunother 1996, 43(November (3)):152-157.
2. Slovin S.F., Keding S.J., Ragupathi G. Carbohydrate vaccines as immunotherapy for cancer. Immunol Cell Biol 2005, 83(August (4)):418-428.
3. Vliegenthart J.F. Carbohydrate based vaccines. FEBS Lett 2006, 580(May (12)):2945-2950.
4. Dube D.H., Bertozzi C.R. Glycans in cancer and inflammation-potential for therapeutics and diagnostics. Nat Rev Drug Discov 2005, 4(June (6)):477-488.
5. Zhang S., Zhang H.S., Cordon-Cardo C., Reuter V.E., Singhal A.K., Lloyd K.O., et al. Selection of tumor antigens as targets for immune attack using immunohistochemistry: II. Blood group-related antigens. Int J Cancer 1997, 73(September (1)):50-56.
6. Zhang S., Cordon-Cardo C., Zhang H.S., Reuter V.E., Adluri S., Hamilton W.B., et al. Selection of tumor antigens as targets for immune attack using immunohistochemistry: I. Focus on gangliosides. Int J Cancer 1997, 73(September (1)):42-49.
7. Springer G.F. Immunoreactive T and Tn epitopes in cancer diagnosis, prognosis, and immunotherapy. J Mol Med 1997, 75(August (8)):594-602.
8. Springer G.F. T and Tn, general carcinoma autoantigens. Science 1984, 224(June (4654)):1198-1206.
9. Kobata A., Amano J. Altered glycosylation of proteins produced by malignant cells, and application for the diagnosis and immunotherapy of tumours. Immunol Cell Biol 2005, 83(August (4)):429-439.
10. Buskas T., Thompson P., Boons G.J. Immunotherapy for cancer: synthetic carbohydrate-based vaccines. Chem Commun (Camb) 2009, 28(September (36)):5335-5349.
11. Thyagarajan R., Arunkumar N., Song W. Polyvalent antigens stabilize B cell antigen receptor surface signaling microdomains. J Immunol 2003, 170(June (12)):6099-6106.
12. Puffer E.B., Pontrello J.K., Hollenbeck J.J., Kink J.A., Kiessling L.L. Activating B: cell signaling with defined multivalent ligands. ACS Chem Biol 2007, 2(April (4)):252-262.
13. Gosselin E.J., Wardwell K., Gosselin D.R., Alter N., Fisher J.L., Guyre P.M. Enhanced antigen presentation using human Fc gamma receptor (monocyte/macrophage)-specific immunogens. J Immunol 1992, 149(December (11)):3477-3481.
14. Kaiser A., Gaidzik N., Westerlind U., Kowalczyk D., Hobel A., Schmitt E., et al. A synthetic vaccine consisting of a tumor-associated sialyl-T(N)-MUC1 tandem-repeat glycopeptide and tetanus toxoid: induction of a strong and highly selective immune response. Angew Chem Int Ed 2009, 48(41):7551-7555.
15. Kudryashov V., Ragupathi G., Kim I.J., Breimer M.E., Danishefsky S.J., Livingston P.O., et al. Characterization of a mouse monoclonal IgG3 antibody to the tumor-associated globo H structure produced by immunization with a synthetic glycoconjugate. Glycoconj J 1998, 15(March (3)):243-249.
16. Guo Z., Boons G.-J. Carbohydrate-based vaccines and immunotherapies. Wiley series in drug discovery and development 2009, ebrary Inc., Wiley, Hoboken, N.J., Oxford, UK, xviii, 408 p., 8 p. of plates.
17. Buskas T., Li Y., Boons G.J. The immunogenicity of the tumor-associated antigen Lewis(y) may be suppressed by a bifunctional cross-linker required for coupling to a carrier protein. Chemistry 2004, 10(July (14)):3517-3524.
18. Snider D.P., Kaubisch A., Segal D.M. Enhanced antigen immunogenicity induced by bispecific antibodies. J Exp Med 1990, 171(June (6)):1957-1963.
19. Shen L., Lang M.L., Wade W.F. The ins and outs of getting in: structures and signals that enhance BCR or Fc receptor-mediated antigen presentation. Immunopharmacology 2000, 49(September (3)):227-240.
20. Yada A., Ebihara S., Matsumura K., Endo S., Maeda T., Nakamura A., et al. Accelerated antigen presentation and elicitation of humoral response in vivo by FcgammaRIIB- and FcgammaRI/III-mediated immune complex uptake. Cell Immunol 2003, 225(September (1)):21-32.
21. Swanson J.A., Hoppe A.D. The coordination of signaling during Fc receptor-mediated phagocytosis. J Leukoc Biol 2004, 76(December (6)):1093-1103.
22. Ota H., Takashima Y., Hayashi Y., Matsumoto Y. A fusion protein of IgG fc and mouse-derived antigen on the surface of pseudorabies virus particles does not accelerate production of harmful auto-reactive antibodies. J Vet Med Sci 2006, 68(November (11)):1179-1183.
23. Stabila P.F., Wong S.C., Kaplan F.A., Tao W. Cell surface expression of a human IgG Fc chimera activates macrophages through Fc receptors. Nat Biotechnol 1998, 16(December (13)):1357-1360.
24. You Z., Huang X., Hester J., Toh H.C., Chen S.Y. Targeting dendritic cells to enhance DNA vaccine potency. Cancer Res 2001, 61(May (9)):3704-3711.
25. Minguet S., Dopfer E.P., Schamel W.W. Low-valency, but not monovalent, antigens trigger the B-cell antigen receptor (BCR). Int Immunol 2010, 22(March (3)):205-212.
26. Hsu C.T., Ting C.Y., Ting C.J., Chen T.Y., Lin C.P., Whang-Peng J., et al. Vaccination against gonadotropin-releasing hormone (GnRH) using toxin receptor-binding domain-conjugated GnRH repeats. Cancer Res 2000, 60(July (14)):3701-3705.
27. Yankai Z., Rong Y., Yi H., Wentao L., Rongyue C., Ming Y., et al. Ten tandem repeats of beta-hCG 109-118 enhance immunogenicity and anti-tumor effects of beta-hCG C-terminal peptide carried by mycobacterial heat-shock protein HSP65. Biochem Biophys Res Commun 2006, 345(July (4)):1365-1371.
28. Jacques S., Rich J.R., Ling C.C., Bundle D.R. Chemoenzymatic synthesis of GM3 and GM2 gangliosides containing a truncated ceramide functionalized for glycoconjugate synthesis and solid phase applications. Org Biomol Chem 2006, 4(January (1)):142-154.
29. Pan Y., Chefalo P., Nagy N., Harding C., Guo Z. Synthesis and immunological properties of N-modified GM3 antigens as therapeutic cancer vaccines. J Med Chem 2005, 48(February (3)):875-883.
30. Kuduk S.D., Schwarz J.B., Chen X.-T., Glunz P.W., Sames D., Ragupathi G., et al. Synthetic and immunological studies on clustered modes of mucin-related Tn and TF O-linked antigens: the preparation of a glycopeptide-based vaccine for clinical trials against prostate cancer†. J Am Chem Soc 1998, 120(48):12474-12485.
31. Greenberg N.M., DeMayo F., Finegold M.J., Medina D., Tilley W.D., Aspinall J.O., et al. Prostate cancer in a transgenic mouse. Proc Natl Acad Sci USA 1995, 92(April (8)):3439-3443.
32. Cairo C.W., Gestwicki J.E., Kanai M., Kiessling L.L. Control of multivalent interactions by binding epitope density. J Am Chem Soc 2002, 124(February (8)):1615-1619.
33. Dal Porto J.M., Gauld S.B., Merrell K.T., Mills D., Pugh-Bernard A.E., Cambier J. B cell antigen receptor signaling 101. Mol Immunol 2004, 41(July (6-7)):599-613.
34. Lo-Man R., Vichier-Guerre S., Bay S., Deriaud E., Cantacuzene D., Leclerc C. Anti-tumor immunity provided by a synthetic multiple antigenic glycopeptide displaying a tri-Tn glycotope. J Immunol 2001, 166(February (4)):2849-2854.
35. Kagan E., Ragupathi G., Yi S.S., Reis C.A., Gildersleeve J., Kahne D., et al. Comparison of antigen constructs and carrier molecules for augmenting the immunogenicity of the monosaccharide epithelial cancer antigen Tn. Cancer Immunol Immunother 2005, 54(May (5)):424-430.
36. Zaharatos G.J., Yu J., Pace C., Song Y., Vasan S., Ho D.D., et al. HIV-1 and influenza antigens synthetically linked to IgG2a Fc elicit superior humoral responses compared to unmodified antigens in mice. Vaccine 2011, 30(December (1)):42-50.
37. Loureiro S., Ren J., Phapugrangkul P., Colaco C.A., Bailey C.R., Shelton H., et al. Adjuvant-free immunization with hemagglutinin-Fc fusion proteins as an approach to influenza vaccines. J Virol 2011, 85(March (6)):3010-3014.
38. Zhang M.Y., Wang Y., Mankowski M.K., Ptak R.G., Dimitrov D.S. Cross-reactive HIV-1-neutralizing activity of serum IgG from a rabbit immunized with gp41 fused to IgG1 Fc: possible role of the prolonged half-life of the immunogen. Vaccine 2009, 27(February (6)):857-863.
39. Chaudhury C., Mehnaz S., Robinson J.M., Hayton W.L., Pearl D.K., Roopenian D.C., et al. The major histocompatibility complex-related Fc receptor for IgG (FcRn) binds albumin and prolongs its lifespan. J Exp Med 2003, 197(February (3)):315-322.
40. Goletz T.J., Klimpel K.R., Leppla S.H., Keith J.M., Berzofsky J.A. Delivery of antigens to the MHC class I pathway using bacterial toxins. Hum Immunol 1997, 54(May (2)):129-136.
41. Kounnas M.Z., Morris R.E., Thompson M.R., FitzGerald D.J., Strickland D.K., Saelinger C.B. The alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein binds and internalizes Pseudomonas exotoxin A. J Biol Chem 1992, 267(June (18)):12420-12423.
42. Zizzari I.G., Veglia F., Taurino F., Rahimi H., Quaglino E., Belleudi F., et al. HER2-based recombinant immunogen to target DCs through FcgammaRs for cancer immunotherapy. J Mol Med (Berl) 2011, 89(December (12)):1231-1240.
43. Wirguin I., Suturkova-Milosevic L., Briani C., Latov N. Keyhole limpet hemocyanin contains Gal(beta 1-3)-GalNAc determinants that are cross-reactive with the T antigen. Cancer Immunol Immunother 1995, 40(May (5)):307-310.